BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Other News

Teva, Actavis, Apotex, AstraZeneca, Novartis inflammation news

The U.S. Court of Appeals issued a temporary injunction blocking the generic companies from marketing generic versions of asthma drug Pulmicort Respules budesonide in the U.S. pending resolution of AstraZeneca's appeal. As a condition of the injunction, the court ordered that AstraZeneca post a bond of $72 million. The pharma is appealing an April decision from the U.S. District Court for the District of New Jersey ruling that AstraZeneca's U.S. Patent...

Read the full 344 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >